Achilles Therapeutics (STU:698) Short-Term Capital Lease Obligation : €3.34 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Achilles Therapeutics Short-Term Capital Lease Obligation?

Achilles Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €3.34 Mil.

Achilles Therapeutics's quarterly Short-Term Capital Lease Obligation declined from Sep. 2023 (€4.33 Mil) to Dec. 2023 (€3.25 Mil) but then increased from Dec. 2023 (€3.25 Mil) to Mar. 2024 (€3.34 Mil).

Achilles Therapeutics's annual Short-Term Capital Lease Obligation declined from Dec. 2021 (€3.97 Mil) to Dec. 2022 (€3.95 Mil) and declined from Dec. 2022 (€3.95 Mil) to Dec. 2023 (€3.25 Mil).

Achilles Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Achilles Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achilles Therapeutics Short-Term Capital Lease Obligation Chart

Achilles Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

0.44

3.05

3.97

3.95

3.25

Achilles Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial													3.77	4.30	4.33	3.25	3.34

Achilles Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Achilles Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Achilles Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Achilles Therapeutics (STU:698) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (STU:698) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ACHL:USA 698:Germany

Address

245 Hammersmith Road, London, GBR, W6 8PW

Website

https://www.achillestx.com

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics (STU:698) Headlines

No Headlines